Intratympanic/Transtympanic Gentamicin Treatment for Meniere's Disease

Timothy C. Hain, MD Please read our disclaimer Return to Index. Page last modified: December 31, 2007

This page is based on a page on another site of Dr. Hain's, that may be more recently edited.

TTG/ITG defined procedures Where to get it done

The situation has changed greatly with gentamicin treatment in the last few years -- this document has recently been updated to reflect the very good results that have been obtained with a newer protocol - -low dose gentamicin.

Intratympanic gentamicin (ITG) and Transtympanic gentamicin (TTG) defined

Figure 1. Gentamicin (a medication intended to purposefully damage the inner ear to stop dizzy spells in Meniere's disease) is injected through the eardrum using a narrow needle. The drug is left in the middle ear for about 30 minutes, and then allowed to drain out.

In severe cases of episodic vertigo, such as due to Meniere's disease, treatments that deaden the inner ear such as gentamicin injections may be considered. This is usually a last resort treatment for persons who have severe attacks of vertigo. Injections of gentamicin are given through the ear drum, by way of a small needle. This is called "intratympanic gentamicin treatment". Some authors call the same process "transtympanic gentamicin" (e.g. Casani, Nuti et al. 2005), but the "intratympanic" term seems to be much more popular.

This procedure allows one to treat one side, without affecting the other. Recently, the "low dose" protocol with just one or two injections in total spaced 1 month apart, has been rapidly gaining favor. In the past, four injections were given in total, administered on a once/week basis. We do not recommend this procedure at the moment.

The procedure is not (very) painful -- a local anesthetic is used to numb the ear drum. A drop of phenol on the ear drum is one method. The drug is injected, left in the middle ear for 30 minutes, and then an attempt is made to clear it from the middle ear via the ET tube. This last step may be important to obtain reproducible results.

Disability is lessened in patients with Menieres after TTG treatment (Pfleiderer, 1998; Perez et al, 1999) but subjective quality of life is unchanged (Soderman et al, 2001). Dizziness may reoccur one year later, requiring another series of injections. Several authors have reported that tinnitus or fullness may improve substantially after TTG (e.g. Sala, 1997). The long-term effect on hearing is presently unclear.

A substantial advantage of TTG treatment is low cost, compared to alternative destructive treatments (i.e. vestibular nerve section or labyrinthectomy). Most authors find that the control of vertigo is comparable to vestibular nerve section (about 90%). TTG treatment is also intrinsically of very low risk, especially compared to nerve section. Compared to labyrinthectomy, TTG treatment is also lower in risk because there is no need for general anesthesia.

 

Two main variants of ITG/TTG:

Technical details of injecting gentamicin are given here.

Low dose -- our preference

The low dose method involves using 1-2 injections of gentamicin, waiting a month between injections. This variant stops vertigo 66-80% of the time, with no significant side effects at all. The low dose variant is relatively new, and there is not nearly as much data concerning outcome as the high-dose variant.

The 2nd injection is given only if there has been a vertigo spell in the 2 weeks prior. In other words, instead of titrating to the onset of damage to vestibular system (as is done for high-dose ITG/TTG), the criterion is a good effect on the disease. This simple idea seems to result in far better results.

Results of the low-dose variant

In our practice in Chicago, we have had excellent results with the low-dose variant, with excellent control of dizziness (100% so far) with no hearing damage at all. Here are what others have reported:

A single dose treatment was reported by at the Mayo clinic, with 84% response rate of vertigo, and no change in hearing. (Driscoll et al, 1997; Harner et al, 2001) These results are attributed to claims that gentamicin destroys the endolymph secreting dark cells before destroying the sensory vestibular epithelium (Beck, 1978). Against this idea is the lack of a pathological change in dark cells after treatment with intravenous aminoglycosides (Cureoglu et al, 2003). The main alternative to the mechanism being destruction of dark cells is the hypothesis that there is a partial damage to the vestibular hair cells. Recent studies in animals suggest that the type-I hair cells are the most sensitive, and the type-II hair cells are more resiliant.

A recent meta-analysis (Chia, Gamst et al. 2004) reported that low-dose methods such as this have significantly poorer vertigo control (66.7% overall). Nevertheless, this has not been our experience. It also seems very likely that low-dose methods will show greater recurrence 1-2 years later. Still, our take on this is that it is very easy to get another "touch up" injection at 1-2 years, but it is impossible to get one's hearing back after it has been damaged by the more intense protocol.

The long-term results of hearing is unclear at this writing. If low-dose does indeed reduce pressure in the inner ear, it may be that hearing will deteriorate to a lesser extent. At this writing though (2007), this conjecture remains to be proven.

Very low dose -- for older persons

Variant procedures where gentamicin is administered even less frequently than once/month, or in a more dilute solution than is conventional also seem well worth considering. We routinely recommend use of half-dose gentamicin in persons having this done who are over the age of 70.

Against this idea is the conjecture that transtympanic gentamicin rapidly "saturates" binding sites in the inner ear, and thus there is no real difference between giving very low dose or low dose -- but rather it is the number of applications of gentamicin that matter, more than the concentration. We don't think that this conjecture is very likely to be true, but it would be an interesting project for a researcher to investigate.

The low dose of gentamicin over a prolonged time is likely to have a more uniform effect on the ear than brief, concentrated administrations (Pender, 2003), and also would seem likely to pose much lower risk to hearing.

High dose:

In the high dose variant, more gentamicin is given over a shorter period of time. This variant works more often (90% of the time), but also is accompanied by far more risk.

Injections are generally given every week, up to a total of 4-6. The treatment is stopped when vertigo ensues, indicating that the gentamicin is affecting the inner ear. In other words, the treatment is continued until there is evidence of damage to the inner ear.

Rarely, even after 6 injections, vertigo cannot be induced and vestibular function remains normal. At this point, treatment is stopped and another method of eliminating vestibular function is used (such as labyrinthectomy).

Vertigo gets worse for a while: After treatment is stopped, vertigo usually lasts from 7-10 days, but may take as long as a month to resolve. Symptoms are controlled with vestibular suppressants and medications for nausea. Good family support or admission to the hospital is required at this point. Unsteadiness usually resolves after several months, but in older individuals, some unsteadiness may be permanent (although vertigo spells are stopped).

Hearing may worsen. In small mammals, such as guinea pigs, application of gentamicin to the round window area may result in near total loss of hearing (e.g. Imamura et al, 2003). It should be noted, however, that small mammals like this have much thinner round window membranes than humans, and therefore may get a much larger amount of gentamicin over the same period of time.

Hearing is not nearly as sensitive in humans, but the reason for this is still being worked out. As protocols evolve, the percentage of treatments associated with hearing reduction continues to gradually be reduced (see table below), but there is still some real risk of hearing loss. A risk of 30% for a mild reduction appears to be "ballpark" at this writing, although recently, better results have been reported (Wu and Minor, 2003).

We believe, based on pharmacokinetic considerations, that protocols where the gentamicin is administered very slowly are less risky to hearing than protocols where a large amount of medication is administered over a week or less. If a patient has already lost usable hearing on the "bad" side, then the risk is eliminated, and either a slow or quick protocol can be used.

 

Figure 2: The goal of high dose intratympanic gentamicin treatment is to reduce or eliminate vestibular function from one ear. This causes an imbalance between the two ears, and a spontaneous nystagmus or jumping of the eyes. This figure illustrates a video-eng tracing. Normally, the eyes are still (the trace would be flat)

Figure 2 above shows the expected result of high-dose gentamicin -- spontaneous nystagmus and vertigo. This is the hoped for result in a person who has had high-dose gentamicin. We have also noted that all patients with successful high-dose gentamicin have strong vibration induced nystagmus.

There is also a movie of something similar in a low-dose protocol patient: at http://www.dizziness-and-balance.com/sitecd.htm

See itg.avi (8 meg). Nystagmus was observed 2 weeks after a single dose of intratympanic gentamicin. This is not common, and was an adverse effect of the single dose protocol.

Results of high dose variant

Results, in terms of relief from vertigo, are typically very good (see table). Hearing is generally unaffected or worsened, and may continue to worsen even after vertigo spells are stopped. Tinnitus is also generally unaffected but some recent studies report reduction in tinnitus. Some patients get relief from Meniere's symptoms in spite of a subtotal ablation of vestibular function. This is attributed to selective damage of gentamicin to the dark cells of the labyrinth (Atlas, 1999; Pender, 1985).

In support of this idea is the observation that TTG reduces the size of the summating potential of ECOG , which is a diagnostic test for Meniere's disease (Adamonis et al, 2000). Against this idea is the lack of a change in dark cells after treatment with intravenous aminoglycosides (Cureoglu et al, 2003).

 

Authors number patients treated response (vertigo) % hearing reduced Comment
Schuknecht, 1957 5 100 100 Treatment with Streptomycin, not Gentamicin
Beck and Schmidt, 1978 118 90 58  
Rauch and Oas, 1997 21 95.2 24-38 30% relapse rate at 1 year
Nedzelski,1993 30 100 27  
Hirsch, 1997 28 91 33  
Sala T, 1997. 21 86 19% 19% hearing better
Micco, 1997 10 90 30 Weekly Injections
Pfleiderer, 1998 16 87 6 Catheter system used, TID for 4 days.
Eklund S, et al, 1999 93 not reported, but presumably very high 10% deafened. Tinnitus improved. as many as 10 injections were used
Minor, 1999 34 91% 3% deafness 22% recurred
Atlas and Parnes, 1999 68 84-90 17% worse, 26% better Weekly injections
Bauer PW, MacDonald CB, Cox LC, 2000 6 "all" Not relevant In non-servicable ears
Abou-Halawa and Poe, 2002 44 80% 14% One patient deafened
(Wu et al. 2003) 34   17% 15% hearing improved
Perez et al, 2003 71 83% 11/71 reduced at 2 years 27 mg/ml concentration. Treatment ended when signs of vestibular paresis began. 50% loss of caloric function.

Flanagan, Mukherjee et al. 2005

56 83% 21% Average loss of 18.5 db

Other variant intratympanic gentamicin procedures -- generally not good ideas

Before beginning, it should be noted that in the past, most practitioners used the simple protocol of about 4 injections of gentamicin, delivered weekly, stopping when there is signs of damage (this is called titration). This made sense as in a meta-analysis of variant methods was recently reported by Chia and others (Chia, Gamst et al. 2004), the weekly titration method of delivery had the best results with both the best vertigo control and a trend towards less overall hearing loss. However, right now, in our practice in Chicago as well as in other highly specialized settings, the low-dose protocol has become routine, as we think that it has even less risk and very good results. Because this procedure works so well, the experiments of the past that we detail below have all become somewhat irrelevant.

Streptomycin: Many other variants of the ITG/TTG protocol have been reported. Streptomycin injection (the dihydro form) has been tried in two published studies (e.g. Schuknecht, 1951), with much worse hearing results than gentamicin. This may be caused by the relative selectivity of gentamicin for the vestibular hair cell, compared to dihydro-streptomycin. It would seem, however, that streptomycin sulfate might be equally effective as gentamicin. There would seem to be little advantage in experimenting with streptomycin as gentamicin works very well without appreciable risk to hearing when given at long intervals.

Titration: When to stop treatment is also an issue, especially for the high-dose protocol with weekly injections. Stopping too late might be more toxic to hearing. Our thought is that it is best not to get into this situation in the first place, and use once/month injections. However, there are sometimes situations where one wants to get a lot of drug in fast, and accept more risk to hearing.

Minor (1999) suggested stopping treatment on appearence of spontaneous nystagmus, head-shaking nystagmus or head-thrust sign. Perez et al (2003) used a similar method. While this protocol appears reasonable to us, it is complex, and stopping simply on a significant change in intensity or direction of spontaneous nystagmus, or till a total of 6 treatments have been delivered might be an adequate substitute. Abou-Halawa and Poe stopped treatment or slowed down treatment when a high-frequency hearing loss appeared. Our thought is that this is much too late as hearing is insensitive to gentamicin.

Delivery methods: Numerous methods have been used to deliver gentamicin including direct injection, delivery via a tympanostomy tube, and surgical catheters (Round window m-cath, Durect Corp; Silverstein MicroWick). Either the needle method (low dose) or tympanostomy tube method (high dose where hearing is already gone) seems quite reasonable. Procedures that require surgical placement of a catheter, at this writing, seem unreasonable as they add risk (the surgery) without proof of better results.

Procedures that involve placement of a "wick" in the tympanostomy tube (i.e. the "Silverstein MicroWick(tm)"), do not seem very different than simple use of the tympanostomy tube by itself. We do not doubt that it works, but we are not convinced that the additional effort and cost needed to place the special tympanostomy tube and wick as well as it's subsequent removal, is warranted. It is very difficult to compete with the low-dose procedure in terms of results. It is also difficult to understand the rationale of putting in a constant infusion of a drug, when it is well known in animals that gentamicin accumulates in the ear over many months. In this group of patients, better dizziness results are correlated with worse hearing results (Light et al, 2003)

Extra surgery: Some groups advocate endoscopic exploration of the middle ear and "clearing of adhesions" from the round window niche. It is claimed that adhesions are present in about 20% of round windows. We are dubious that this can be done without additional morbidity to the tympanic membrane (from the endoscope). This procedure also adds a requirement for added cost, specialized equipment and skill to an otherwise rather straightforward procedure.

Timing: With respect to timing, protocols that involve rapid administrations of large amounts of drug (here we define rapid as over one week), seem to be prone to produce worse hearing results, possibly because gentamicin has a delayed and prolonged effect, extending over weeks-months, and it is difficult to know if you have given enough or too much, over a week. (Chia, Gamst et al. 2004) However, if hearing is already unusable on the side to be treated, shorter protocols seem quite reasonable.

Finally, some groups suggest intratympanic dexamethasone treatment -- dexamethasone is a steroid, and not related to gentamicin. At this writing (9/2001), the benefit of this procedure has not been shown clearly -- it may be worth a try in situations where all else has been tried and there is little to lose. Silverstein et al found it to be no better than placebo (1998) For example, it's use might be considered in when the remaining ear affected by Meniere's is the only-hearing ear.

Gentamicin vs. steroids vs. vestibular nerve section

There are some complex judgements that come up when one needs to have "something done" about Meniere's disease. Essentially, it comes down to cost vs. benefit

Method Hearing Risk Effectiveness Durability Other considerations
Steroid injection Minimal Moderate Low Not a logical treatment as doesn't last.
Low dose Gentamicin Minimal High Moderate (1-2 yr) Best choice
High dose gentamicin Moderate High Usually permanent Permanent imbalance not unusual
Labyrinthectomy sure loss High Permanent Permanent imbalance AND hearing loss AND highly invasive
Vestibular nerve section Moderate High Permanent

Permanent imbalance

Highly invasive

In our opinion, low-dose gentamicin is presently the "sweet spot" in this table. We see little reason why any other procedure should be advocated, unless low-dose gentamicin has already failed.

Self-administered gentamicin -- usually not a good idea

The simplest procedure (and the least expensive) reported so far is that of Rutka and colleagues (Rutka, 2002). They had simply had the patient administer topical gentamicin themselves through a ventilation tube. A tube is placed in the posterio-inferior quadrant of the TM. Patients are instructed to lie on their side and place 5-6 drops into the affected ear 3 times/day. A low concentration of gentamicin is used -- 3 mg/ml combined with 1mg/ml of betamethasone. This concentration and total dose/day (3 mg) is about 10 times weaker than those used with weekly needle injections (30 mg). They were told to administer the drops until they became constantly vertiginous for 2 days and then stop. Most patients experienced ototoxicity after 12 days of this treatment.

About 50% of patients experienced worsening of hearing and about 40% of patients developed permanent perforations of their eardrums. These results are MUCH WORSE than those associated with single-dose gentamicin. The perforation complication was thought to be a result of the steroid component (Rutka, 2003).

In our opinion, this procedure is less precise than most of the other procedures noted above, and the lack of precision is probably associated with greater hearing risk. Nevertheless, it seems reasonable in situations where hearing is unusable, as an alternative to a surgical labyrinthectomy. As mentioned, it might be preferable to use drops without steroids because of the danger of a permanent perforation. Also, use of less drops per day might result in better hearing results although a longer latency before toxicity begins. We don't think that use of steroids here is a good idea, as it seems to bring on another complication.

Adding other agents to the gentamicin -- also not a good idea

Some groups have experimented with adding other agents to gentamicin, apparently in an attempt to make the solution more viscous and less likely to run down the eustachian tube as soon as the patient sits up. For example, fibrin glue (!?) has been used for this purpose (Casani, Nuti et al. 2005). We do not suggest this procedure. As the problem in the past has mainly been hearing toxicity, procedures that are aimed to increase the dose delivered to the ear would seem irrational unless the ear is already deaf.

Why might TTG fail ?

There are a number of reasons why ITG/TTG might fail. First, the diagnosis might be wrong. The patient might have a central disorder (such as Migraine associated vertigo-- which is at least 25 times more common than Meniere's disease), the patient might have a nerve disorder (such as microvascular compression), or might have bilateral Meniere's. Disorders of the vestibular nerve would not be expected to respond to TTG.

A second group of reasons depend on the drug not being effective. In theory, it might be ineffective because it isn't delivered to the inner ear (perhaps due to adhesions over the round window, or drug exiting the ear via the eustachian tube), the individual being treated might have an idiosyncratic resistance to gentamicin (idiosyncratic susceptibility has been documented, perhaps there is also resistance), or there might be recovery of hair cells that are incompletely damaged. In this regasrd, initially, gentamicin may do reversible damage to the hair cells. It is common for Meniere's attacks to return 1 or 2 years after the first TTG treatment (Waele et al, 2002). One can be more certain that TTG has killed a significant portion of the inner ear by doing vestibular testing, especially caloric testing. Because of the possibility of reversible damage, one might need to do a caloric about 3 months after the end of treatment (to see the peak response), and do another one if dizziness recurs a year or two later.

Patients with otolithic crises of Tumarkin (a variant of Meniere's) might be particularly likely to fail as this is an otolithic disorder, and gentamicin is thought by some to be less toxic to the otoliths than to the canals in humans. In our opinion, this is incorrect as recent data (Picciotti et al, 2005; Helling et al, 2007) suggests that gentamicin first affects the saccule (one of the two otolith organs), so the picture may be complex. Abou-Halawa and Poe (2002) reported that of 4 patients with Tumarkin crises, 2 had no further attacks, 1 did not respond, and 1 had a recurrence of attacks requiring additional gentamicin.

When TTG fails, careful consideration should be made to exclude failures in the first group (wrong diagnosis). If the diagnosis still appears to be sustainable, then one may wish to consider more radical procedures such as vestibular nerve section or labyrinthectomy.

Where to get intratympanic gentamicin treatment

This is an outpatient procedure. Nearly all major medical centers now offer intratympanic gentamicin treatment through their otolaryngology service. Before having intratympanic gentamicin treatment, we also think that it is prudent to try all reasonable medical avenues of treatment.

We do not think that one needs to try the numerous treatments for Meniere's that are probably placebos, as these waste time and money, and low-dose gentamicin is very effective. Examples of procedures that are probably placebos or at least only slightly effective, are the Menniett device, intratympanic steroids, and shunt surgery.

References related to intratympanic gentamicin treatment:

Web site and all contents Copyright December 31, 2007 , Timothy C. Hain, M.D., All rights reserved.
Last saved on December 31, 2007